Edgestream Partners L.P. Decreases Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Edgestream Partners L.P. lessened its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 66.4% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 90,870 shares of the biopharmaceutical company’s stock after selling 179,294 shares during the quarter. Edgestream Partners L.P.’s holdings in Amicus Therapeutics were worth $901,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in FOLD. Vanguard Group Inc. grew its holdings in shares of Amicus Therapeutics by 5.0% in the fourth quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock worth $404,308,000 after acquiring an additional 1,360,613 shares during the period. Perceptive Advisors LLC grew its stake in shares of Amicus Therapeutics by 1.3% during the 4th quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock valued at $398,135,000 after purchasing an additional 364,539 shares during the period. Wellington Management Group LLP increased its position in shares of Amicus Therapeutics by 101.9% during the 4th quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after purchasing an additional 7,666,335 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Amicus Therapeutics by 20.1% in the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock worth $162,713,000 after purchasing an additional 2,307,385 shares during the period. Finally, William Blair Investment Management LLC boosted its holdings in shares of Amicus Therapeutics by 12.8% in the second quarter. William Blair Investment Management LLC now owns 13,003,363 shares of the biopharmaceutical company’s stock worth $128,993,000 after buying an additional 1,477,084 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of analysts have commented on FOLD shares. Jefferies Financial Group started coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 target price for the company. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Friday, August 9th. JPMorgan Chase & Co. lowered their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price target on shares of Amicus Therapeutics in a report on Friday. Finally, Wells Fargo & Company started coverage on Amicus Therapeutics in a research note on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.00.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $10.34, for a total transaction of $77,550.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $9,168,002.36. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $10.34, for a total transaction of $77,550.00. Following the completion of the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,168,002.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,866,540. The disclosure for this sale can be found here. Insiders have sold a total of 21,100 shares of company stock worth $226,375 in the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $11.29 on Friday. The stock has a 50-day moving average price of $11.04 and a 200 day moving average price of $10.71. The stock has a market capitalization of $3.34 billion, a P/E ratio of -23.04 and a beta of 0.69. Amicus Therapeutics, Inc. has a 12-month low of $9.02 and a 12-month high of $14.57. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The firm had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. During the same quarter last year, the business posted ($0.15) earnings per share. The company’s revenue for the quarter was up 34.0% compared to the same quarter last year. Equities research analysts forecast that Amicus Therapeutics, Inc. will post -0.08 EPS for the current fiscal year.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.